Background: Colorectal Adenomatous Polyp (CAP) was one precursor of colorectal cancer (CRC) and having a high chance of developing into CRC. There was a lack of conclusive chemoprevention evidences to prevention new CAP occurrence in post-polypectomy. Xiaoai Jiedu Decoction, Chinese National Medical Professor (Zhou Zhongying)'s experience formula, has been used to treat new CAP occurrence in post-polypectomy from the 20th century in China. However, clinical research of Xiaoai Jiedu Decoction in the treatment of CAP recurrence was lack. We design this study to evaluate the efficacy and safety of Xiaoai Jiedu Decoction in the treatment of new CAP occurrence in post-polypectomy on colonoscopy.

Methods/design: A randomized, controlled, blind and multicenter trial to evaluate the efficacy and safety of Xiaoai Jiedu Decoction is proposed. CAP patients (after complete polypectomy under colonoscopy) will be randomly assigned into Xiaoai Jiedu Decoction group and Xiaoai Jiedu Decoction mimetic agent group. Patients will receive 6-course treatments and a 2-year follow-up. Follow-up colonoscopy will be anticipated to perform in 1 and 2 years after the baseline examinations. The primary outcome measure is the new CAP occurrence in 1 and 2 years. The secondary outcome measure is the occurrence of advanced adenoma in 1 and 2 years.

Discussion: This study will provide objective evidences to evaluate the efficacy and safety of Xiaoai Jiedu Decoction as an adjuvant treatment for new CAP occurrence in post-polypectomy.

Trial Registration: NCT03616444.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708956PMC
http://dx.doi.org/10.1097/MD.0000000000016680DOI Listing

Publication Analysis

Top Keywords

xiaoai jiedu
32
jiedu decoction
32
cap occurrence
20
occurrence post-polypectomy
16
treatment cap
12
evaluate efficacy
12
efficacy safety
12
safety xiaoai
12
xiaoai
8
jiedu
8

Similar Publications

Ethnopharmacological Relevance: The Xiaoai Jiedu recipe (XJR) is a traditional Chinese medicine formulation used in clinical settings to treat liver cancer. It has shown promising effectiveness by combining herbal and animal-derived ingredients, offering a new approach to cancer treatment. However, its mechanism of action is poorly understood.

View Article and Find Full Text PDF

Objective: Network pharmacology is an emerging discipline that applies computational methods to understand drug actions and interactions with multiple molecular targets. Xiao'ai Jiedu is a valued traditional Chinese medicine preparation for which the mechanism of action is not yet established. This study aims to explore the mechanism of Xiao'ai Jiedu in treating lung cancer through network pharmacology.

View Article and Find Full Text PDF
Article Synopsis
  • Xiao-Ai Jie-Du decoction (XAJDD) is traditionally used to treat diffuse large B-cell lymphoma (DLBCL) with varying prescriptions tailored to patients' conditions.* -
  • The study aimed to identify the core ingredients of XAJDD and understand how they work against DLBCL using data mining and in silico modeling.* -
  • The core formula includes six herbs, and key components like astibin and quercetin were found to significantly inhibit DLBCL cell proliferation and promote apoptosis, helping to reveal the treatment's molecular mechanisms.*
View Article and Find Full Text PDF

Introduction: Xiaoai Jiedu recipe (XJR), a classical prescription of traditional Chinese medicine (TCM), has been clinically proven to be effective in ameliorating colorectal cancer (CRC). However, its exact mechanism of action is still elusive, limiting its clinical application and promotion to a certain extent. This study aims to evaluate the effect of XJR on CRC and further illustrate mechanism underlying its action.

View Article and Find Full Text PDF

Purpose: Xiaoai Jiedu recipe (XJR), a formula long used by Chinese National Medical Professor Zhou Zhongying, has potent antitumor properties, but the molecular mechanism is still unclear. The aim of the study was to investigate the antitumor mechanism of XJR on hepatocellular carcinoma (HCC) by focusing on miRNA.

Methods: Three concentrations of XJR (low, middle, and high) were used to treat tumor xenograft mice models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!